HRP20200009T1 - Angiotenzin ii u kombinaciji za liječenje hipotenzije - Google Patents

Angiotenzin ii u kombinaciji za liječenje hipotenzije Download PDF

Info

Publication number
HRP20200009T1
HRP20200009T1 HRP20200009TT HRP20200009T HRP20200009T1 HR P20200009 T1 HRP20200009 T1 HR P20200009T1 HR P20200009T T HRP20200009T T HR P20200009TT HR P20200009 T HRP20200009 T HR P20200009T HR P20200009 T1 HRP20200009 T1 HR P20200009T1
Authority
HR
Croatia
Prior art keywords
preparation
angiotensin
treatment
subject
catecholamine
Prior art date
Application number
HRP20200009TT
Other languages
English (en)
Croatian (hr)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200009(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington University, A Congressionally Chartered Not-For-Profit Corporation filed Critical The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Publication of HRP20200009T1 publication Critical patent/HRP20200009T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20200009TT 2013-12-18 2014-12-18 Angiotenzin ii u kombinaciji za liječenje hipotenzije HRP20200009T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension
EP14872684.7A EP2986308B1 (en) 2013-12-18 2014-12-18 Angiotensin ii in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
HRP20200009T1 true HRP20200009T1 (hr) 2020-03-20

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200009TT HRP20200009T1 (hr) 2013-12-18 2014-12-18 Angiotenzin ii u kombinaciji za liječenje hipotenzije

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR102399383B1 (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (1) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (1) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT3607962T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (1) PL2986308T3 (enExample)
PT (2) PT3607962T (enExample)
RS (1) RS59804B1 (enExample)
SI (1) SI2986308T1 (enExample)
SM (2) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
KR20170026486A (ko) * 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
US9919022B2 (en) 2015-03-20 2018-03-20 Arthur J. ATKINSON, JR. Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2017120440A1 (en) * 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
EP1401864A1 (en) 2001-06-04 2004-03-31 Human Genome Sciences Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
DE602006021600D1 (de) 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
AU2006332449B2 (en) 2005-12-30 2008-05-15 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
BR112013000744A2 (pt) 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
AU2014256944B2 (en) 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
KR20170026486A (ko) 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
WO2017120440A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
KR20220028125A (ko) 2022-03-08
KR20240154702A (ko) 2024-10-25
US11559559B2 (en) 2023-01-24
JP6824739B2 (ja) 2021-02-03
CA2933601A1 (en) 2015-06-25
DK2986308T3 (en) 2020-01-27
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
AU2014364528A1 (en) 2016-06-30
US20180193407A1 (en) 2018-07-12
EP3607962B1 (en) 2025-08-13
MX380968B (es) 2025-03-12
AU2014364528C1 (en) 2021-01-07
NZ721089A (en) 2022-10-28
AU2014364528B2 (en) 2020-08-27
US9220745B2 (en) 2015-12-29
MX2020011190A (es) 2020-11-13
AU2020277230A1 (en) 2020-12-24
DK3607962T3 (da) 2025-11-17
US10493124B2 (en) 2019-12-03
WO2015095535A1 (en) 2015-06-25
FI3607962T3 (fi) 2025-11-24
RS59804B1 (sr) 2020-02-28
KR20230051721A (ko) 2023-04-18
JP2017501154A (ja) 2017-01-12
AU2024219851A1 (en) 2024-10-10
JP2019214610A (ja) 2019-12-19
KR102399383B1 (ko) 2022-05-19
CN119700926A (zh) 2025-03-28
JP7175506B2 (ja) 2022-11-21
CN112546197A (zh) 2021-03-26
BR112016013961A2 (pt) 2017-10-10
AU2014364528A9 (en) 2016-07-28
EA037823B1 (ru) 2021-05-25
HUE047062T2 (hu) 2020-04-28
EP3607962A1 (en) 2020-02-12
SMT202000018T1 (it) 2020-03-13
JP2022137224A (ja) 2022-09-21
CN106061493A (zh) 2016-10-26
JP2025114753A (ja) 2025-08-05
US20190070250A1 (en) 2019-03-07
US20230226141A1 (en) 2023-07-20
LT2986308T (lt) 2020-03-25
PT2986308T (pt) 2020-01-21
US10765722B2 (en) 2020-09-08
CY1122604T1 (el) 2021-03-12
CN111920939A (zh) 2020-11-13
EP2986308B1 (en) 2019-10-16
EP2986308A1 (en) 2016-02-24
MX2016008108A (es) 2017-03-09
US10028995B2 (en) 2018-07-24
US20150164980A1 (en) 2015-06-18
US20220047669A1 (en) 2022-02-17
IL246162B (en) 2020-03-31
IL246162A0 (en) 2016-07-31
ES2771749T3 (es) 2020-07-07
SMT202500427T1 (it) 2026-01-12
LT3607962T (lt) 2026-01-12
US20160129072A1 (en) 2016-05-12
SI2986308T1 (sl) 2020-03-31
PT3607962T (pt) 2025-11-18
WO2015095535A9 (en) 2016-07-14
US20190328827A1 (en) 2019-10-31
EP2986308A4 (en) 2017-01-11
EA201691258A1 (ru) 2016-11-30
PL2986308T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
HRP20200009T1 (hr) Angiotenzin ii u kombinaciji za liječenje hipotenzije
PH12017502092A1 (en) Topical pharmaceutical compositions
EA201490254A1 (ru) Комбинированное лечение гепатита с
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
WO2015095811A3 (en) Combination therapy with neoantigen vaccine
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA033257B1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
MX373231B (es) Agente anticancerigeno.
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX377688B (es) Métodos para administrar óxido nítrico a la sangre arterial o arterializada.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2020011107A (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
MX389088B (es) Métodos para tratar el vhc.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
EA201690070A1 (ru) Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза
EA201690686A1 (ru) Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection